Otsuka Pharmaceutical to Acquire Astex

Japan’s Otsuka has agreed to purchase cancer specialist, Astex Pharmaceuticals, in a deal which is valued at $886 million. Otsuka will obtain the remaining shares of Astex for $8.50 per share in cash, signifying a 48% premium to the average closing stock price for the prior 30-day period. One of the main reasons behind the

Continue Reading

Incyte Shares Jump, After Positive Phase II Results for Jakafi

Shares in Incyte increased by almost 34% yesterday after the company announced promising mid-stage data for their pancreatic cancer therapy, Jakafi. Positive results from a Phase II clinical trial showed that the JAK inhibitor, Jakafi (ruxolitinib), when used in combination with Roche’s Xeloda (capecitabine), improved survival in some patients with recurrent or treatment refractory advanced

Continue Reading

Amgen Finalises Agreement With Servier

Amgen have confirmed a new partnership with Servier to boost the pipelines of both businesses. The waiting period to let any antitrust concerns to arise has now passed, meaning the two companies can advance with the agreement. The deal will provide Amgen with rights in the US to Servier’s heart drug, ivabradine, which has already

Continue Reading

Novo Nordisk Post Strong Q2 Results

Novo Nordisk has announced another strong set of results, aided by strong sales of their diabetes drug, Victoza. The company’s net profit for the second quarter increased by 26% to 6.73 billion Danish kroner (equal to roughly $1.20 billion), while sales grew 10% to 21.38 billion kroner. The organisation’s group of modern insulin products, including

Continue Reading

Icon Posts Strong Quarter 2 Results

Icon have announced that they have reviewed their guidance for revenues and earnings per share in fiscal year (FY) 2013 after posting another strong financial quarter. Earlier this week, Icon reported net revenues for their second quarter of US $334.2 million, an increase of 20.6% year on year, comfortably passing the forecast of US $321.8

Continue Reading

Eli Lilly Reveals Strong Q2 Results

Eli Lilly yesterday posted a strong set of financials for the second quarter of 2013, and announced that they would be raising their forecast for the full-year.  The Q2 results were aided by cost-cutting and strong sales of their blockbuster drug, Cymbalta. Net income soared by 36% to $1.25 billion, while turnover increased 6% to

Continue Reading

J&J Report Strong Second Quarter Results

Johnson & Johnson have reported strong results for their second quarter of 2013, with an 8.5% increase in sales.  The increase was aided by robust results from their prostate cancer drug, Zytiga. Net income reached $3.83 billion, a major increase from the $1.41 billion from the previous year’s quarter 2 period, aided by the gain

Continue Reading

AstraZeneca announces new Cambridge Biomedical Campus

Pharmaceutical giant AstraZeneca has announced it is setting up its new global headquarters, just south of Cambridge. The £330million research and development site will employ a skilled workforce of 2,000 people and will open by 2016. Research and Development will cease at Alderley Park in Cheshire and close its London headquarters. Many of these posts will

Continue Reading

If 8 areas of NHS activity were improved then vast amounts of money for CCGS could be saved

If the National Health Service improved just 8 areas of their activity then 212 of England’s Clinical Commissioning Groups (CCGs) would save more than £1.6 billion. Statistics were analysed in research by consultancy MedeAnalytics. This covers all patient-level activity and associated costs taking place in hospitals in England. From analysis, researchers have narrowed down 8

Continue Reading